Skip to main content
. 2020 Jul 26;21(15):5304. doi: 10.3390/ijms21155304

Figure 2.

Figure 2

(A) Schematic representation of neuromyelitis optica spectrum disorder (NMOSD) pathogenesis: currently available treatments and their targets are reported. ADCC, antibody-dependent cell-mediated cytotoxicity; AQP4-IgG, anti-aquaporin-4 immunoglobulin G; NK, natural killer; MMF, mycophenolate mofetil; aza, azathioprine. (B) Allogeneic HSCT rationale and immunological implications.